Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Necchi

Showing results (31-40 of 495) with videos related to

Pageof 50
Sort By:
European Urology|May 7, 2018
Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical InterventionJuan Chipollini, Andrea Necchi, Philippe E Spiess
The New England Journal of Medicine|October 17, 2019
Erdafitinib in Urothelial Carcinoma. ReplyYohann Loriot, Andrea Necchi, Arlene O Siefker-Radtke
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2019
Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell TumorsAndrea Necchi, Jeffrey S Ross, Philippe E Spiess
Urologic Oncology|March 17, 2009
Understanding the somatic-type malignant differentiation in male germ-cell cancer: a work in progress. Response to the article by Spiess et al., Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol 2008;26:595-9Andrea Necchi, Nicola Nicolai, Maurizio Colecchia, et al.
Urologic Oncology|July 21, 2020
The new era of precision urobiome: RE: "Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study" by Chipollini et alMassimo Alfano, Filippo Pederzoli, Marco Bandini, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 26, 2022
Geography Should Not Be an "Oncologic Destiny" for Urothelial Cancer: Improving Access to Care by Removing Local, Regional, and International BarriersMonika Joshi, Hyma Polimera, Tracey Krupski, et al.
Urologic Oncology|May 5, 2019
Updates in the molecular epidemiology and systemic approaches to penile cancerJacob J Adashek, Andrea Necchi, Philippe E Spiess
European Urology|March 6, 2022
Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into OpportunitiesLaura Marandino, Daniele Raggi, Andrea Necchi, et al.
The Journal of Urology|April 10, 2023
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. LetterMarco Moschini, Andrea Necchi, Alberto Briganti, et al.
European Urology|January 27, 2023
Reply to Chao Quan, Jinbo Chen, and Jiao Hu's Letter to the Editor re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107-14Giuseppe Basile, Marco Bandini, Francesco Montorsi, et al.
Pageof 50

Showing results (31-40 of 495) with videos related to

Sort By:
Pageof 50
European Urology|May 7, 2018
Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical InterventionJuan Chipollini, Andrea Necchi, Philippe E Spiess
The New England Journal of Medicine|October 17, 2019
Erdafitinib in Urothelial Carcinoma. ReplyYohann Loriot, Andrea Necchi, Arlene O Siefker-Radtke
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2019
Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell TumorsAndrea Necchi, Jeffrey S Ross, Philippe E Spiess
Urologic Oncology|March 17, 2009
Understanding the somatic-type malignant differentiation in male germ-cell cancer: a work in progress. Response to the article by Spiess et al., Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol 2008;26:595-9Andrea Necchi, Nicola Nicolai, Maurizio Colecchia, et al.
Urologic Oncology|July 21, 2020
The new era of precision urobiome: RE: "Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study" by Chipollini et alMassimo Alfano, Filippo Pederzoli, Marco Bandini, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 26, 2022
Geography Should Not Be an "Oncologic Destiny" for Urothelial Cancer: Improving Access to Care by Removing Local, Regional, and International BarriersMonika Joshi, Hyma Polimera, Tracey Krupski, et al.
Urologic Oncology|May 5, 2019
Updates in the molecular epidemiology and systemic approaches to penile cancerJacob J Adashek, Andrea Necchi, Philippe E Spiess
European Urology|March 6, 2022
Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into OpportunitiesLaura Marandino, Daniele Raggi, Andrea Necchi, et al.
The Journal of Urology|April 10, 2023
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. LetterMarco Moschini, Andrea Necchi, Alberto Briganti, et al.
European Urology|January 27, 2023
Reply to Chao Quan, Jinbo Chen, and Jiao Hu's Letter to the Editor re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107-14Giuseppe Basile, Marco Bandini, Francesco Montorsi, et al.
Pageof 50